What is Fusion Pharmaceuticals?
Fusion Pharmaceuticals is at the forefront of oncology innovation, specializing in the development of targeted alpha therapies (TATs). The company's approach involves linking alpha particle-emitting isotopes to specific targeting molecules, enabling the precise delivery of therapeutic payloads directly to tumor cells. Fusion's lead program, FPI-1434, which targets the insulin-like growth factor 1 receptor (IGF-1R), is currently undergoing Phase 1 clinical trials. The company's pipeline also features FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), which has received Investigational New Drug (IND) clearance and is set to enter Phase 1 studies, alongside FPI-2059, a small molecule designed to target neurotensin receptor 1 (NTSR1). Beyond its proprietary pipeline, Fusion has established key collaborations with industry giants AstraZeneca and Merck, aiming to explore novel TATs and combination therapies with existing oncology treatments.
How much funding has Fusion Pharmaceuticals raised?
Fusion Pharmaceuticals has raised a total of $362.5M across 4 funding rounds:
Series A
$25M
Series B
$105M
Unspecified
$20M
Stock Offering
$212.5M
Series A (2017): $25M with participation from Genesys Capital, Facit, HealthCap Partners, TPG Biotech, and JJDC
Series B (2019): $105M led by Varian and OrbiMed
Unspecified (2020): $20M supported by CPP Investments
Stock Issuance/Offering (2020): $212.5M, investors not publicly disclosed
Key Investors in Fusion Pharmaceuticals
Genesys Capital
Genesys Capital is a venture capital firm based in Toronto, focusing on early-stage life sciences and healthcare companies, investing in biotechnology and medical innovation across North America.
CPP Investments
CPP Investments, founded in 2002 and headquartered in Ontario, Canada, is a professional investment management organization that holds or owns securities of companies other than banks.
TPG Biotech
TPG is a global investment firm managing alternative assets and supporting business growth across diverse industries, providing investment management, advisory, and capital solutions worldwide.
What's next for Fusion Pharmaceuticals?
The substantial enterprise-level funding and recent strategic investment position Fusion Pharmaceuticals for accelerated growth and pipeline expansion. The company's focus on precision oncology through radiopharmaceuticals, coupled with strategic partnerships with global pharmaceutical leaders like AstraZeneca and Merck, indicates a strong trajectory. Future developments will likely involve advancing its clinical programs, particularly FPI-1434 and FPI-1966, through further trial phases and potentially expanding its manufacturing capabilities to support its growing portfolio of targeted alpha therapies. This capital infusion is expected to fuel research and development, clinical trial execution, and market penetration strategies in the competitive oncology landscape.
See full Fusion Pharmaceuticals company page
